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BACKGROUND: Studies evaluating vitamin D status in relation to pancreatic cancer risk have yielded inconsistent results.
METHODS: We prospectively followed 118597 participants in the Nurses’ Health Study and Health Professionals Follow-up Study from
1986 to 2006. We calculated a 25-hydroxyvitamin D (25(OH)D) score from known predictors of vitamin D status for each individual
and then examined the predicted 25(OH)D levels in relation to pancreatic cancer risk. Relative risks (RRs) and 95% confidence
intervals (95% CIs) were estimated using Cox proportional hazards models adjusted for age, sex, race, height, smoking, and diabetes.
We then further adjusted for body mass index (BMI) and physical activity in a sensitivity analysis.
RESULTS: During 20 years of follow-up, we identified 575 incident pancreatic cancer cases. Higher 25(OH)D score was associated with
a significant reduction in pancreatic cancer risk; compared with the lowest quintile, participants in the highest quintile of 25(OH)D
score had an adjusted RR of 0.65 (95% CI¼0.50–0.86; Ptrend¼0.001). Results were similar when we further adjusted for BMI and
physical activity.
CONCLUSIONS: Higher 25(OH)D score was associated with a lower risk of pancreatic cancer in these two prospective cohort studies.
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The role of vitamin D in carcinogenesis has attracted increasing
attention in recent years. Certain observational studies have
reported a protective association between sufficient vitamin D
status and lower risk of colon, breast, prostate, and ovarian
cancers (Garland et al, 2006). Experimental studies showed
that vitamin D has anticancer properties, including inducing
differentiation, initiating apoptosis, and inhibiting proliferation,
angiogenesis, and metastasis (Giovannucci, 2005). Pancreatic
cancer cells express vitamin D receptors (VDRs) (Colston et al,
1997) and high levels of 25(OH)D3-1a-hydroxylase, an enzyme
that converts 25(OH)D to the active metabolite, 1,25-dihydroxy-
vitamin D (1,25(OH)2D) (Schwartz et al, 2004). In addition, 1,25
vitamin D analogs inhibit pancreatic cancer cell line growth
in vitro (Colston et al, 1997; Schwartz et al, 2004) and pancreatic
tumour growth in vivo (Colston et al, 1997). Therefore, vitamin D
may have a role in the development of pancreatic cancer.
However, studies evaluating vitamin D status in relation to
pancreatic cancer risk have yielded inconsistent results. To
evaluate the impact of vitamin D status in a larger population,
we developed a model to predict long-term plasma 25(OH)D levels.
This 25(OH)D score takes into account the combined influence of
many of the major determinants of vitamin D status. In previous
analyses, the score was correlated with plasma 25(OH)D levels and
was inversely associated with total cancer mortality and pancreatic
cancer incidence in men (follow-up up to 2000; number of
pancreatic cancer cases¼170) (Giovannucci et al, 2006). In this
study, we assessed the relation between predicted long-term
vitamin D status and pancreatic cancer risk in both men and
women and with additional follow-up (up to 2006), and further
examined the potential effect modifications by other factors, using
data collected from the Nurses’ Health Study (NHS) and the Health
Professionals Follow-up Study (HPFS).
MATERIALS AND METHODS
In 1976, the NHS cohort was established when 121700 US female
registered nurses aged 30–55 years answered a baseline ques-
tionnaire on risk factors for cancer and cardiovascular disease.
Every 2 years, participants receive follow-up questionnaires to
update information on potential risk factors and new cancer
and disease diagnoses. Dietary information was first collected
in 1980 through a food frequency questionnaire, and is
updated in alternate follow-up cycles; leisure-time physical activity
was assessed in the 1986 questionnaire. Blood samples were
provided by 32826 participants aged 43–70 years from 1989
to 1990.
In 1986, the HPFS cohort was established when 51529 male
dentists, optometrists, osteopaths, podiatrists, pharmacists, and
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tionnaire on risk factors for cancer, cardiovascular disease, and
diabetes. A follow-up questionnaire is sent to participants every 2
years requesting an update on nondietary exposures and medical
history, with dietary history updated every 4 years. Blood samples
were provided by 18018 participants from 1993 to 1995.
The overall follow-up rate was over 90% in both cohorts. For the
present analysis, we excluded individuals with a history of cancer
up to 1986, leaving a cohort of 118597 participants eligible (45226
men and 73371 women). This study was approved by the human
subjects committee at Brigham and Women’s Hospital and the
Harvard School of Public Health. All participants provided
informed consent for questionnaire and blood data to be used in
research studies.
In both cohorts, when a participant (or next of kin for
decedents) reported a diagnosis of pancreatic cancer on a
follow-up questionnaire, we asked permission to obtain the
participant’s medical records. We also searched the National
Death Index to identify deaths among non-respondents. If the
primary cause of death on the death certificate was a previously
unreported pancreatic cancer case, we contacted a family member
to obtain permission to retrieve medical records. Study physicians
at the NHS and HPFS who were masked to the exposure data
reviewed medical records and assigned cancer diagnoses and
causes of death. In this study, 90% of the pancreatic cancer cases
were confirmed by medical record review.
Derivation of the 25(OH)D prediction score has been described
previously (Giovannucci et al, 2006). Briefly, we used a sample of
1095 men in the HPFS who had available plasma 25(OH)D
measurements and who were free of diagnosed cancer at the time
of blood draw. With the measured plasma 25(OH)D concentration
as the dependent variable, linear regression was performed using
race, geographic region, vitamin D intake, body mass index (BMI),
and leisure-time physical activity as independent predictors of
plasma 25(OH)D. Then, on the basis of the predictors’ regression
coefficients from the sample, a 25(OH)D score was calculated for
each cohort member. To validate this model, we calculated the
25(OH)D score for an independent sample of 542 men in the HPFS
who also had available measurements of circulating 25(OH)D
(Giovannucci et al, 2006). The actual plasma concentration rose
across increasing deciles of 25(OH)D score (Ptrend o0.001), and
the difference in the mean actual 25(OH)D concentration between
extreme deciles was 10ngml
 1, similar to the difference of
11ngml
 1, which we calculated from the initial dataset
(1ngml
 1¼2.496nmoll
 1). In addition, in a separate analysis of
47800 men, 25(OH)D score had a significantly inverse association
with colorectal cancer, which is compatible with plasma-based
studies (Giovannucci et al, 2006). We then applied this method to
women and calculated 25(OH)D score for all the participants in
our study cohort using baseline race and geographic region, and
values of leisure-time physical activity, BMI, and vitamin D intake
reported in the 1986 questionnaire (when leisure-time physical
activity was first assessed).
We collected information on height, race, and geographic
regions from the 1986 HPFS questionnaire and the 1976 NHS
questionnaire, the only questionnaires in which these variables
were assessed. BMI (kgm
 2) was calculated using height (reported
in 1986 for HPFS and in 1976 for NHS) and weight was reported in
the 1986 questionnaires for both cohorts. Information on cigarette
smoking, physical activity, history of diabetes, multivitamin use,
and dietary factors was also obtained from the 1986 questionnaires
for both cohorts.
Statistical analyses
We computed person-time from the return date of the 1986
questionnaire to the date of pancreatic cancer diagnosis, death
from any cause, or the end of follow-up (30 June 2006 in the NHS,
and 31 January 2006 in the HPFS), whichever came first. Relative
risks (RRs) and 95% confidence intervals (CIs) were estimated by
Cox proportional hazards models with age (in years) as the
primary time scale. The proportional hazards assumption was
verified by modelling interaction terms of age and our main
exposures as well as other fixed covariates. We first analysed the
HPFS and the NHS separately; and if similar RRs were obtained,
we would then perform a pooled analysis with adjustment for
cohort. 25-Hydroxyvitamin D score was analysed in quintiles
based on predicted levels, with the lowest quintile as the reference
group. Quintiles were based on the distribution observed in the
entire study population. In multivariate models, we adjusted for
sex, race (Caucasian, African American, other), height (inches in
quintiles), cigarette smoking (never, past, current o15 cigarettes
per day, current 15–35 cigarettes per day, current 435 cigarettes
per day), and diabetes (yes/no). We considered the possibility that
the 25(OH)D score might be acting as a surrogate for other risk
factors of pancreatic cancer, such as BMI or physical activity,
which were both in the prediction equation. We therefore further
adjusted for BMI (kgm
 2 in quintiles) and physical activity
(MET-h per week in quintiles) in the multivariate model. An
indicator variable for missing values of each covariate was created.
Linear trends were tested by the Wald test of a score variable that
contained median values of 25(OH)D quintiles.
We performed subgroup analyses to examine whether the
association of 25(OH)D score with pancreatic cancer varies across
strata of sex (also across strata of study, as HPFS consisted of only
men and NHS of only women), age at baseline (o60 or X60
years), follow-up duration (o10 or X10 years), geographic region
(northern or southern), smoking (never or ever), BMI (o25 or
X25kgm
 2), physical activity (below or above median, 8.7 MET-h
per week), dietary vitamin D intake (below or above median,
288IU per day), calcium intake (below or above median, 888mg
per day), multivitamin use (no or yes), and use of supplemental
vitamin D (no or yes). We also examined whether retinol intake
(below or above median, 2669 IU per day) modified the association
between 25(OH)D score and pancreatic cancer because retinol can
compete with vitamin D for binding to the retinoid X receptor
(Giovannucci, 2005). Tests for interaction were performed by the
Wald test using cross-product term of predicted 25(OH)D quintile
trend with the stratification variables.
In sensitivity analyses, we excluded the first 2 years of follow-up
for all participants to rule out an effect of subclinical pancreatic
cancer on 25(OH)D levels. We also did a subgroup analysis
including only Caucasians. For analyses among men or women, we
repeated our analyses using sex-specific quintiles, which yielded
consistent results with those based on quintiles generated from the
entire population. Excluding cases with missing medical records
(10% of all cases) had no impact on the estimates. All analyses
used SAS software, version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
With 2226169 person-years accrued over 20 years of follow-up,
a total of 575 pancreatic cancer cases were identified (273 men
and 302 women). The median predicted 25(OH)D level was
29.2ngml
 1 in men and 27.6ngml
 1 in women. Participants with
higher 25(OH)D score were more likely to be Caucasian, live in
southern states, have a lower BMI, report higher physical activity,
have higher vitamin D intake, and were less likely to be current
smokers or have a history of diabetes (Table 1).
We pooled the HPFS and the NHS together because their designs
were similar and no significant differences in the risk estimates
were found when the two studies were analysed separately (Table 3,
the stratified analysis by sex). Higher 25(OH)D score was
associated with a significant reduction in risk (Table 2). Compared
with individuals with 25(OH)D scores in the lowest quintile, those
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0.86; Ptrend¼0.001) for pancreatic cancer. This result remained
largely unchanged after further adjusting for BMI and physical
activity or after excluding the first 2 years of follow-up (Table 2).
Restricting to Caucasians had little impact on the estimates (data
not shown).
Associations with 25(OH)D score were examined across strata of
other factors (Table 3). No statistically significant interactions
were found; higher predicted 25(OH)D remained inversely related
to risk across most subgroups. We noted that there was a trend
towards a greater impact of higher 25(OH)D scores on risk among
participants of older age, southern region, nonsmokers, low
physical activity, low dietary vitamin D intake, low retinol intake,
no multivitamin use, and no supplemental vitamin D use (Table 3).
DISCUSSION
In our study, higher 25(OH)D score was associated with a
significantly lower risk of pancreatic cancer. This inverse
association was consistent across gender and strata of other
covariates. There are several mechanisms through which vitamin D
may affect pancreatic cancer risk. Pancreatic cancer cells express
VDRs (Colston et al, 1997) and 25(OH)D3-1a-hydroxylase
(Schwartz et al, 2004), which metabolises 25(OH)D to the active
1,25(OH)2D vitamin D form. Binding of VDRs by 1,25(OH)2D
leads to increased differentiation and apoptosis as well as
reduced proliferation, invasiveness, angiogenesis, and metastasis
(Giovannucci, 2005); and experimental studies have shown that
1,25(OH)2D analogs inhibit growth of pancreatic cancer cells
Table 1 Baseline characteristics by predicted plasma 25(OH)D, 1986
Predicted plasma 25(OH)D
a
Characteristic Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
N 23670 23840 23643 23673 23771
Range 25(OH)D (ngml
 1) 7.3–25.2 25.2–27.4 27.4–29.1 29.1–31.1 31.2–38.6
Median 25(OH)D (ngml
 1) 23.4 26.4 28.3 30.0 32.6
Mean age (years) 52.7 53.1 53.3 53.5 53.6
Race (%)
White 88.70 94.75 95.32 96.07 96.36
Black 4.87 0.42 0.14 0.02 0
Other 6.43 4.83 4.54 3.91 3.64
Residence (%)
North-east 61.5 51.5 49.4 41.0 37.4
Mid-west/west 28.3 27.8 26.6 26.9 25.3
South 10.2 20.7 24.0 32.1 37.3
Mean height (inches) 65.2 66.5 66.8 67.4 67.3
Mean body mass index (kgm
 2) 29.1 26.2 24.6 24.1 23.1
Median physical activity (MET-h per week) 5.8 9.0 13.6 20.1 34.5
Smoking (%)
Current 20.4 18.3 17.5 14.2 12.3
Past 35.0 37.9 38.3 40.0 39.8
Never 44.6 43.8 44.2 45.8 47.9
Diabetes (%) 5.8 3.9 2.9 2.9 2.3
Mean vitamin D intake (IU per day) 200.8 288.8 343.2 431.0 570.2
Abbreviations: 25(OH)D¼25-hydroxyvitamin D; MET¼metabolic equivalents; h¼hour; IU¼international units.
aQuintiles were generated from the Nurses’ Health Study and
the Health Professionals Follow-Up Study combined.
Table 2 RRs and 95% CIs of pancreatic cancer by predicted plasma 25(OH)D, 1986–2006
Predicted plasma 25(OH)D
a
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 Ptrend
b
Range 25(OH)D (ngml
 1) 7.3–25.2 25.2–27.4 27.4–29.1 29.1–31.1 31.2–38.6
Median 25(OH)D (ngml
 1) 23.4 26.4 28.3 30.0 32.6
Cases (n¼575) 125 121 115 112 102
Person-years 444248 445340 443622 443944 449015
Age/sex-adjusted 1.00 0.84 (0.66–1.09) 0.77 (0.59–1.00) 0.71 (0.54–0.92) 0.63 (0.48–0.83) o0.001
Multivariate
c 1.00 0.85 (0.65–1.09) 0.77 (0.59–1.00) 0.72 (0.55–0.94) 0.65 (0.50–0.86) 0.001
Multivariate+BMI+activity
d 1.00 0.85 (0.65–1.11) 0.77 (0.57–1.04) 0.72 (0.52–1.00) 0.67 (0.46–0.96) 0.03
Multivariate+BMI+activity, excluding
the first 2 years of follow-up
e
1.00 0.85 (0.65–1.12) 0.76 (0.56–1.04) 0.69 (0.50–0.97) 0.66 (0.46–0.96) 0.02
Abbreviations: 25(OH)D¼25-hydroxyvitamin D; BMI¼body mass index; CI¼confidence interval; RR¼relative risk.
aQuintiles were generated from the Nurses’ Health Study
and the Health Professionals Follow-Up Study combined.
bCalculated by using median predicted plasma 25(OH)D as a continuous variable.
cAdjusted for age, sex (cohort), race
(Caucasian, African American, other), height (inches in quintiles), cigarette smoking (never, past, current o15 cigarettes per day, current 15–35 cigarettes per day, current 435
cigarettes per day), and diabetes (yes or no).
dIn addition, adjusted for body mass index (kgm
 2 in quintiles) and physical activity (MET-h per week in quintiles).
eCases/person-
years: 556/1989401.
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In addition, pancreatic islet cells express VDRs and 25(OH)
D3-1a-hydroxylase, and in vitro and in vivo evidence supports
that vitamin D deficiency impairs endocrine pancreatic function
(Pittas et al, 2007). Observational studies have shown that
vitamin D status is inversely associated with development of type
2 diabetes or metabolic syndrome (Mattila et al, 2007; Pittas
et al, 2007; Forouhi et al, 2008). As diabetes, hyperglycaemia,
and insulin resistance have been linked to pancreatic cancer
development, vitamin D may act to decrease pancreatic cancer
risk by improving glucose metabolism and reducing insulin
resistance.
Epidemiological studies have used four approaches to examine
the association of pancreatic cancer with vitamin D status, and
their results have been inconsistent. Sunlight exposure, a major
source of vitamin D in humans, was inversely correlated with
pancreatic cancer in ecological studies conducted in North
America, Europe, and Japan (Mizoue, 2004; Boscoe and Schymura,
2006; Grant, 2007). Higher dietary vitamin D intake as well as
higher total vitamin D intake (from foods and supplements) was
related to lower risk in the NHS and the HPFS (Skinner et al, 2006)
but not in a cohort of male Finnish smokers enrolled in the Alpha-
Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study
(Stolzenberg-Solomon et al, 2002). Directly measured circulating
Table 3 RRs and 95% CIs of pancreatic cancer by predicted plasma 25(OH)D according to other factors, 1986–2006
Predicted plasma 25(OH)D
a
Cases Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 Ptrend
b Pinteraction
c
Sex 0.75
Male (HPFS) 273 1.00 0.88 (0.55–1.42) 0.71 (0.43–1.19) 0.64 (0.37–1.11) 0.66 (0.35–1.21) 0.12
Female (NHS) 302 1.00 0.79 (0.56–1.13) 0.81 (0.55–1.21) 0.80 (0.52–1.24) 0.64 (0.39–1.04) 0.10
Age at baseline (years) 0.41
o60 298 1.00 0.76 (0.52–1.10) 0.83 (0.55–1.24) 0.78 (0.50–1.22) 0.76 (0.46–1.26) 0.34
X60 277 1.00 0.93 (0.63–1.37) 0.70 (0.45–1.08) 0.65 (0.41–1.05) 0.57 (0.33–0.97) 0.02
Follow-up (years) 0.60
o10 225 1.00 1.01 (0.66–1.55) 0.70 (0.43–1.16) 0.85 (0.50–1.43) 0.68 (0.37–1.25) 0.19
X10 350 1.00 0.75 (0.53–1.06) 0.81 (0.56–1.17) 0.65 (0.43–0.99) 0.66 (0.41–1.05) 0.07
Region 0.62
Northern 289 1.00 0.82 (0.57–1.18) 0.97 (0.65–1.44) 0.94 (0.60–1.47) 0.83 (0.49–1.41) 0.65
Southern 286 1.00 0.90 (0.59–1.37) 0.63 (0.39–1.01) 0.61 (0.37–1.01) 0.58 (0.33–1.01) 0.03
Smoking 0.16
Never 222 1.00 0.81 (0.52–1.24) 0.73 (0.45–1.17) 0.65 (0.39–1.10) 0.40 (0.22–0.74) 0.01
Ever 353 1.00 0.86 (0.61–1.22) 0.79 (0.54–1.16) 0.75 (0.50–1.15) 0.88 (0.56–1.40) 0.50
Body mass index (kgm
 2) 0.77
o25 271 1.00 0.76 (0.42–1.38) 0.82 (0.46–1.47) 0.70 (0.38–1.28) 0.57 (0.31–1.07) 0.05
X25 304 1.00 0.87 (0.64–1.20) 0.69 (0.47–1.03) 0.69 (0.44–1.09) 0.83 (0.47–1.49) 0.14
Physical activity (MET-h per week) 0.58
o8.7 (median) 305 1.00 0.82 (0.60–1.12) 0.73 (0.51–1.06) 0.73 (0.48–1.13) 0.40 (0.20–0.80) 0.01
X8.7 270 1.00 0.95 (0.54–1.66) 0.89 (0.51–1.56) 0.81 (0.46–1.43) 0.86 (0.47–1.55) 0.58
Dietary vitamin D intake (IU per day) 0.67
o288 (median) 277 1.00 0.64 (0.45–0.91) 0.58 (0.38–0.89) 0.38 (0.22–0.65) 0.34 (0.17–0.67) o0.01
X288 298 1.00 0.87 (0.53–1.42) 0.69 (0.41–1.17) 0.78 (0.45–1.35) 0.71 (0.38–1.30) 0.30
Retinol (IU per day) 0.23
o2669 (median) 280 1.00 0.70 (0.48–1.00) 0.65 (0.43–1.00) 0.55 (0.34–0.91) 0.42 (0.23–0.78) 0.01
X2669 295 1.00 0.86 (0.56–1.33) 0.71 (0.44–1.13) 0.71 (0.43–1.16) 0.75 (0.43–1.29) 0.29
Calcium (mg per day) 0.29
o888 (median) 307 1.00 0.85 (0.59–1.21) 0.86 (0.57–1.28) 0.65 (0.41–1.04) 0.76 (0.44–1.30) 0.19
X888 268 1.00 0.81 (0.53–1.24) 0.65 (0.41–1.04) 0.75 (0.47–1.22) 0.59 (0.34–1.02) 0.08
Multivitamin use 0.77
No 335 1.00 0.75 (0.54–1.05) 0.61 (0.42–0.91) 0.56 (0.36–0.88) 0.42 (0.23–0.74) o0.01
Yes 240 1.00 0.87 (0.52–1.46) 0.89 (0.52–1.52) 0.82 (0.47–1.45) 0.89 (0.48–1.64) 0.78
Supplemental vitamin D use 0.95
No 346 1.00 0.72 (0.52–1.00) 0.59 (0.40–0.87) 0.59 (0.38–0.92) 0.47 (0.26–0.85) o0.01
Yes 229 1.00 1.02 (0.57–1.83) 1.03 (0.56–1.88) 0.85 (0.45–1.61) 0.86 (0.43–1.72) 0.50
Abbreviations: 25(OH)D¼25-hydroxyvitamin D; MET¼metabolic equivalents; h¼hour; IU¼international units; CI¼confidence interval; RR¼relative risk. When applicable,
adjusted for age, sex (cohort), race (Caucasian, African American, other), height (inches in quintiles), body mass index (kgm
 2 in quintiles), physical activity (MET-h per week in
quintiles), cigarette smoking (never, past, current o15 cigarettes per day, current 15–35 cigarettes per day, current 435 cigarettes per day), and diabetes (yes or no).
aQuintiles
were generated from the Nurses’ Health Study and the Health Professionals Follow-Up Study combined.
bCalculated by using median predicted plasma 25(OH)D as a
continuous variable.
cCalculated by Wald test using cross-product term of predicted plasma 25(OH)D quintile trend with the stratification variables.
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dietary sources, was positively associated with pancreatic cancer
risk in male Finnish smokers (fifth vs first quintile, RR¼2.92, 95%
CI¼1.56–5.48) (Stolzenberg-Solomon et al, 2006) but not in a
cohort of the Prostate, Lung, Colorectal, and Ovarian (PLCO)
Screening Trial (fifth vs first quintile, RR¼1.45, 95% CI¼0.66–
3.15) (Stolzenberg-Solomon et al, 2009). In contrast, the vitamin D
prediction score, which also accounts for sun exposure (by using
residential state and physical activity as surrogates) and vitamin D
intake, was inversely associated with pancreatic cancer risk in the
present two US prospective cohort studies (NHS and HPFS)
(Giovannucci et al (2006) and this study).
However, participants in the ATBC study might not be
comparable with those in the American studies, as they were all
current smokers and lived at higher latitude. In this study, we
observed a stronger inverse association with vitamin D among
nonsmokers and among those living in southern states. The PLCO
study also found a significant interaction by geographic region
(Pinteraction¼0.015): they reported a positive association of risk
with plasma vitamin D concentrations among those living in
northern latitudes, but no association was observed among those
living in southern latitudes (Stolzenberg-Solomon et al, 2009).
Another difference in the ATBC study population concerns dietary
pattern: a major dietary source of vitamin D in the Finns does not
tend to be from fortified dairy products or breakfast cereal as
American populations but from vitamin D-rich fish that may
contain some pancreatic carcinogen such as organochlorine
compounds (Stolzenberg-Solomon et al, 2006). In addition, both
the ATBC study and the PLCO study were based on one
measurement of 25(OH)D in blood, which most likely reflects
recent exposure to sources of vitamin D rather than long-term
average vitamin D level; whereas the 25(OH)D prediction score
would track well over time because factors that influence the score,
such as race and residential region, are immutable or relatively
stable. As evidence of this supposition, in a previous study, the
correlation between two direct plasma measurements 4 years apart
was 0.70, whereas the correlation between the two 25(OH)D scores
was 0.83 (Giovannucci et al, 2006).
Retinol has been hypothesised to counteract the cancer
prevention effects of vitamin D, possibly acting through competi-
tion with vitamin D for the retinoid X receptor (Giovannucci,
2005). In this study, we observed that the inverse association
between vitamin D status and pancreatic cancer was more
pronounced among those with lower intake of retinol; we also
observed a stronger inverse association among those who did not
use multivitamins or supplemental vitamin D. We have previously
reported an increased pancreatic cancer risk associated with
multivitamin use (Skinner et al, 2004), so it is possible that some
factor in multivitamin supplements other than vitamin D,
potentially retinol, antagonises the protective effect of vitamin D
or increases risk independently.
One concern of our approach is that the 25(OH)D score may
act as a surrogate for other potential risk factors, such as
BMI or physical activity. A higher BMI and less physical activity
have previously been associated with increased pancreatic
cancer risk in our cohorts (Michaud et al, 2001). However, our
results for predicted 25(OH)D did not change when adjusted for
BMI or physical activity, which suggests that total vitamin status,
rather than simply low BMI or physical activity, is driving the
significant inverse association. We are also aware that
the prediction score has been developed in men; however, given
the prospective design, any misclassification of the 25(OH)D score
among women tended to be non-differential, and therefore
would only bias the results towards the null. In addition, when
we stratified the analyses by gender, similar RRs were obtained for
men and women, with no significant interactions. To rule out
the possibility that vitamin D status might be changed by
preclinical pancreatic cancer at baseline, we excluded the first
2 years of follow-up for all participants in sensitivity analyses.
The results were unchanged. Residual confounding by smoking
was not likely because a stronger association was observed among
never smokers. Residual confounding by other measured factors
might be of minor importance in this study, as our age/sex-
adjusted models and multivariate models yielded very similar
results.
The strengths of our study include its prospective design, use of
a validated prediction score taking into account both diet and sun
exposure, comprehensive information on many potential con-
founders, a large sample size that allowed us to stratify the data by
potential effect modifiers, and 20 years of follow-up with a high
follow-up rate. Because the participants were health professionals,
the accuracy of self-reported data is likely to be high; moreover,
any misclassification of vitamin D status is likely to be random and
would therefore have attenuated rather than exaggerated a true
association.
In conclusion, our data suggest that higher 25(OH)D levels may
significantly decrease the risk of pancreatic cancer. Given the
growing epidemic of vitamin D insufficiency in the US population
(Ginde et al, 2009), more epidemiological research is needed,
particularly prospective studies with repeated measures of plasma
25(OH)D. If the association between vitamin D and pancreatic
cancer is causal, many with low vitamin D levels might benefit
from increased vitamin D status for pancreatic cancer risk
reduction.
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